Clinical trials in Meldola – page 16

439 clinical trials in Meldola, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Meldola at a glance

439

clinical trials

Paediatric trials0
Research sites1

Quick filters

439 trials in Meldola

Open in trial search

Prostate cancer

Recruiting

Study on the Use of [18F]PSMA-1007 PET/CT Imaging for Detecting Prostate Cancer in Patients with Newly Diagnosed High-Risk or Very-High-Risk Conditions

Registered drugNo placebo

Study on the Use of [18F]PSMA-1007 PET/CT Imaging for Detecting Prostate Cancer in Patients with Newly Diagnosed High-Risk or Very-High-Risk Conditions

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:(2S)-2-[[(1S)-1-Carboxy-5-[[(2S)-2-[[4-[[[(2S)-4-Carboxy-2-[[(2S)-4-Carboxy-2-[(6-(18F)Fluoranylpyridine-3-Carbonyl)Amino]Butanoyl]Amino]Butanoyl]Amino]Methyl]Benzoyl]Amino]-3-Naphthalen-2-Ylpropanoyl]Amino]Pentyl]Carbamoylamino]Pentanedioic Acid
Sponsor:Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH

Contact Research Centre

Gastrooesophageal cancer+1

Recruiting

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Registered drugNo placebo

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anhydrous Docetaxel
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Colorectal adenocarcinoma

Recruiting

Study of Pre-Operative Treatments with Sotorasib and Drug Combination for Patients with Resectable Colorectal Cancer

Registered drugNo placebo

Study of Pre-Operative Treatments with Sotorasib and Drug Combination for Patients with Resectable Colorectal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Darolutamide
Sponsor:Unicancer

Contact Research Centre

Biliary neoplasm

Recruiting

Study on Cisplatin, Gemcitabine, and Paclitaxel Albumin-Bound for Patients with Resectable Biliary Tract Cancer at High Risk of Recurrence

Registered drugNo placebo

Study on Cisplatin, Gemcitabine, and Paclitaxel Albumin-Bound for Patients with Resectable Biliary Tract Cancer at High Risk of Recurrence

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Neuroendocrine tumour+1

Recruiting

Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

Registered drugNo placebo

Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Contact Research Centre

Leiomyosarcoma+1

Recruiting

Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo

Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dacarbazine
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Belumosudil Mesilate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Endometrial cancer+2

Recruiting

Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

Registered drugNo placebo

Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Arcagy Gineco

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 233 cities in Italy

Clinical research in Meldola

What the registry says about research in the country

01 Hematologic Malignancies

Innovative research focusing on blood cancers, including studies of novel therapeutic combinations for acute myeloid leukemia, multiple myeloma, and various lymphomas.

Advanced treatments for diffuse large B-cell lymphoma
Multiple myeloma therapies for transplant-ineligible patients
Novel approaches in myelodysplastic syndrome

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Solid Tumors

Comprehensive research into advanced solid tumors, with particular emphasis on colorectal cancer, non-small cell lung cancer, and breast cancer.

Targeted therapies for metastatic colorectal cancer
Novel combinations for advanced NSCLC
Innovative approaches in metastatic breast cancer

Investigations focus on personalized treatment strategies and novel drug combinations.

03 Genitourinary Cancers

Groundbreaking studies in urological cancers, including research on prostate cancer, urothelial cancer, and renal cell carcinoma.

Advanced treatments for metastatic prostate cancer
Maintenance therapy in urothelial cancer
Immunotherapy approaches in renal cell carcinoma

Research aims to improve survival rates through innovative therapeutic strategies.

Back to Italy All countries